16:36 EDT Plus Therapeutics (PSTV) files to sell 1.57B shares of common stock for holders
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Promising Outlook for Plus Therapeutics: Buy Rating Affirmed Amid Clinical and Financial Advancements
- Plus Therapeutics’ Optimistic Earnings Call Highlights
- Promising Outlook for Plus Therapeutics: Strategic Financial Moves and Innovative Assay Launch Justify Buy Rating
- Plus Therapeutics price target lowered to $5.50 from $8 at H.C. Wainwright
- Plus Therapeutics Reports 2024 Financial Results and Progress